Prescient Therapeutics (PTX) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of solid and hematological cancers.
The Company’s novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.
September 2016 Appendix 4C – Quarterly
First Patient at Moffitt dosed in Phase 1b/2 breast trial
Rodman & Renshaw Global Investment Conference Presentation
PTX presents at Rodman & Renshaw Investment Conference
Appendix 4G and Corporate Governance Statement
Appendix 4E and 2016 Annual Report